Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Tom DeKoning"'
Autor:
George F. Vande Woude, Sean G. Buchanan, Bryn Eagleson, Tom DeKoning, Dafna Kaufman, Rich West, Liang Kang, Yanli Su, Curt Essenburg, Ben Staal, Yu-Wen Zhang
Supplementary Methods, Figures 1-4 from MET Kinase Inhibitor SGX523 Synergizes with Epidermal Growth Factor Receptor Inhibitor Erlotinib in a Hepatocyte Growth Factor–Dependent Fashion to Suppress Carcinoma Growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::142738c7ff8b0261fd24c3de26bc3ab1
https://doi.org/10.1158/0008-5472.22383012
https://doi.org/10.1158/0008-5472.22383012
Autor:
George F. Vande Woude, Sean G. Buchanan, Bryn Eagleson, Tom DeKoning, Dafna Kaufman, Rich West, Liang Kang, Yanli Su, Curt Essenburg, Ben Staal, Yu-Wen Zhang
The hepatocyte growth factor (HGF)-MET pathway supports several hallmark cancer traits, and it is frequently activated in a broad spectrum of human cancers (http://www.vai.org/met/). With the development of many cancer drugs targeting this pathway, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a53e2b62ddd13214cd7e5dc034b1cdec
https://doi.org/10.1158/0008-5472.c.6500394
https://doi.org/10.1158/0008-5472.c.6500394
Autor:
Liang Kang, Andrea Worschech, Maria Libera Ascierto, Valeria De Giorgi, Mark A. Enter, Timothy J. O'Rourke, Francesco M. Marincola, Yanli Su, Curt J. Essenburg, Qian Xie, Lisa Kefene, George F. Vande Woude, Tom DeKoning, Dafna Kaufman, Julie Koeman, Ena Wang, Robert D. Bradley
Because oncogene MET and EGF receptor (EGFR) inhibitors are in clinical development against several types of cancer, including glioblastoma, it is important to identify predictive markers that indicate patient subgroups suitable for such therapies. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd5c452738bc0aa1d38d6e6e846628bd
https://europepmc.org/articles/PMC3258605/
https://europepmc.org/articles/PMC3258605/
Autor:
Ben Staal, Liang Kang, Yanli Su, Dafna Kaufman, Tom DeKoning, Curt J. Essenburg, Yu-Wen Zhang, Sean Buchanan, Bryn Eagleson, George F. Vande Woude, Richard A. West
Publikováno v:
Cancer research. 70(17)
The hepatocyte growth factor (HGF)-MET pathway supports several hallmark cancer traits, and it is frequently activated in a broad spectrum of human cancers (http://www.vai.org/met/). With the development of many cancer drugs targeting this pathway, t
Autor:
Liang Kang, Andrea Worschech, Mark A. Enter, Valeria De Giorgi, Curt J. Essenburg, Dafna Kaufman, Robert Bradley, Timothy J. O'Rourke, George F. Vande Woude, Ena Wang, Francesco M. Marincola, Qian Xie, Lisa Kefene, Yanli Su, Tom DeKoning, Julie Koeman
Publikováno v:
Cancer Research. 71:LB-223
Due to its invasive nature, glioblastoma (GBM) is the most aggressive brain cancer. Hepatocyte growth factor (HGF) binds to MET tyrosine kinase receptor and induces invasive tumor growth. As MET inhibitors are entering clinical trials against several
Autor:
Dafna Kaufman, Liang Kang, Rich West, Curt J. Essenburg, Sean Buchanan, Tom DeKoning, Bryn Eagleson, George F. Vande Woude, Yu-Wen Zhang, Yanli Su, Ben Staal
Publikováno v:
Cancer Research. 70:LB-305
The signaling cascade originating from hepatocyte growth factor/scatter factor (HGF/SF)-MET ligand-receptor pair is frequently observed in a broad spectrum of human cancers. Inappropriate activation of this pathway has been shown to occur via: paracr